Simultaneous kissing stents (SKS) technique for treating bifurcation lesions in medium-to-large size coronary arteries.
The treatment of bifurcation lesions (BLs) is associated with high procedural complication and restenosis rates. Two techniques of BL interventions were compared: the simultaneous kissing stents (SKS) technique, involving 2 stents, 1 in the main vessel and 1 in the side branch (n = 100), and the conventional stent strategy (CSS) technique, involving a stent in the main vessel and provisional stenting for the side branch (n = 100). In-hospital and 30-day major adverse cardiac events were greater in the CSS group, with significantly less procedure time with the SKS technique. The incidence of target lesion revascularization was 5% in the SKS group and 18% in the CSS group (p = 0.007). Therefore, the SKS technique seems to be rapid, safe, and effective for the treatment of medium- to large-size BLs, with a trend toward fewer acute complications and promising mid-term results.
Sharma
Samin K
SK
Cardiac Catheterization Laboratory of the Cardiovascular Institute, Mount Sinai Hospital, New York, New York 10029-6574, USA. samin.sharma@msnyuhealth.org <samin.sharma@msnyuhealth.org>
Choudhury
Ahsan
A
Lee
Johnny
J
Kim
Michael C
MC
Fisher
Edward
E
Steinheimer
Angelica M
AM
Kini
Annapoorna S
AS
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D019917:Blood Vessel Prosthesis Implantation / Q000379:methods*; D000077144:Clopidogrel; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy*; D003331:Coronary Vessels / Q000473:pathology / Q000601:surgery; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form; D018572:Disease-Free Survival; D004867:Equipment Design / Q000295:instrumentation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007527:Isoenzymes / Q000097:blood; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000097:blood / Q000209:etiology; D009518:New York; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011183:Postoperative Complications / Q000097:blood / Q000209:etiology; D012720:Severity of Illness Index; D015607:Stents; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D020099:Coated Materials, Biocompatible; D007140:Immunoglobulin Fab Fragments; D007527:Isoenzymes; D010975:Platelet Aggregation Inhibitors; D019210:Troponin I; D000077144:Clopidogrel; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D013988:Ticlopidine; D000077284:Abciximab